Cargando…

Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults

INTRODUCTION: Adintrevimab is a fully human immunoglobulin G1 extended half-life monoclonal antibody that was developed to have broad neutralization against SARS-CoV, SARS-CoV-2, and other SARS-like CoVs with pandemic potential. Here we report the safety, pharmacokinetics (PK), serum viral neutraliz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmidt, Pete, Gong, Jean, Narayan, Kristin, Gupta, Deepali, Engler, Frank, Li, Yong, Copans, Amanda, Campanaro, Ed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127981/ https://www.ncbi.nlm.nih.gov/pubmed/37185797 http://dx.doi.org/10.1007/s40121-023-00794-1

Ejemplares similares

Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)
por: Ison, Michael G, et al.
Publicado: (2023)

633. Preliminary Results from a Phase 1 Single Ascending-Dose Study Assessing Safety, Serum Viral Neutralizing Antibody Titers (sVNA), and Pharmacokinetic (PK) Profile of ADG20: an Extended Half-Life Monoclonal Antibody Being Developed for the Treatment and Prevention of Coronavirus Disease (COVID-19)
por: Paguntalan, Helen, et al.
Publicado: (2021)

Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron
por: Ison, Michael G, et al.
Publicado: (2023)

Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19
por: Zumbrun, Elizabeth E., et al.
Publicado: (2022)

Pharmacokinetics and Immunogenicity of Broadly Neutralizing HIV Monoclonal Antibodies in Macaques
por: Rosenberg, Yvonne, et al.
Publicado: (2015)

1363. Preliminary Safety Results from a Phase 1 First in Human Study of VYD222: an Extended Half-Life Monoclonal Antibody (mAb) in Development for COVID-19 Prevention
por: Mahoney, Kathryn, et al.
Publicado: (2023)

A Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of JDTic
por: Buda, Jeffrey J, et al.
Publicado: (2015)

Double-Blind, Placebo-Controlled, Dose-Escalating Study Evaluating the Safety and Immunogenicity of an Epitope-Specific Chemically Defined Nanoparticle RSV Vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2023)

A Double-Blind, Placebo-Controlled Trial Demonstrating the Safety, Tolerability, and Pharmacokinetics of Single, Escalating Oral Doses of RTI-336
por: Carroll, F. Ivy, et al.
Publicado: (2018)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG(2) Monoclonal Antibody, in Healthy Volunteers
por: Mathur, Mohit, et al.
Publicado: (2022)

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques
por: Shingai, Masashi, et al.
Publicado: (2014)

Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: Results from a randomized, double-blind, phase-2, placebo-controlled study
por: Hershberger, Ellie, et al.
Publicado: (2019)

A Randomized, Double‐Blind, Placebo‐Controlled, Multiple Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of ELX‐02 in Healthy Subjects
por: Leubitz, Andi, et al.
Publicado: (2021)

Efficacy, Safety and Pharmacokinetics of IL-17 Monoclonal Antibody Injection (AK111) in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blinded, Placebo-Controlled Phase Ib Multidose Escalation Clinical Study
por: Jiang, Congjun, et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study
por: Li, Yinjuan, et al.
Publicado: (2021)

First‐in‐human, randomized, double‐blind, placebo‐controlled, dose escalation trial of the anti‐herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers
por: Blank, Antje, et al.
Publicado: (2022)

Safety and Pharmacokinetics of the Oral TYK2 Inhibitor PF‐06826647: A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalation Study
por: Singh, Ravi Shankar P., et al.
Publicado: (2020)

Rapid determination of SARS-CoV-2 antibody neutralization titer using Bio-Rad Bio-Plex correlates strongly with pseudovirus-determined neutralization titer
por: Heaps, Amy L., et al.
Publicado: (2023)

A randomized, double-blind, placebo controlled safety, tolerability, and pharmacokinetic dose escalation study of a gentamicin vancomycin gel in patients undergoing colorectal surgery
por: Bennett-Guerrero, Elliott, et al.
Publicado: (2016)

Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting Staphylococcus aureus Cytotoxins in the Lung Epithelial Lining Fluid of Healthy Volunteers
por: Magyarics, Zoltan, et al.
Publicado: (2019)

Safety and Immunogenicity of a Recombinant Tetanus Vaccine in Healthy Adults in China: A Randomized, Double‐Blind, Dose Escalation, Placebo‐ and Positive‐Controlled, Phase 1/2 Trial
por: Xu, Xiaowei, et al.
Publicado: (2021)

Pharmacokinetics of Monoclonal Antibodies
por: Ryman, Josiah T., et al.
Publicado: (2017)

Pharmacokinetics of escalating single‐dose administration of cannabidiol to cats
por: Rozental, Aaron J., et al.
Publicado: (2022)

Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases
por: Li, Zhaoyang, et al.
Publicado: (2023)

Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial
por: Dai, Zhijie, et al.
Publicado: (2023)

Fibre-Optic Surface Plasmon Resonance Biosensor for Monoclonal Antibody Titer Quantification
por: Ly, Thai Thao, et al.
Publicado: (2021)

Anti-feline panleukopenia virus serum neutralizing antibody titer in domestic cats with the negative or low hemagglutination inhibition antibody titer
por: SOMA, Takehisa, et al.
Publicado: (2018)

Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
por: Doevendans, Erik, et al.
Publicado: (2019)

Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition
por: Gilbert, Peter B., et al.
Publicado: (2022)

302. Investigating NAI Titer as a Neutralizing IAV Correlate of Protection
por: Rumfelt, Kalee E, et al.
Publicado: (2023)

Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial
por: Stephenson, Kathryn E., et al.
Publicado: (2021)

Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-Immune Adults: A Phase 1, Double-Blinded Placebo Controlled Dosage Escalation Study
por: Koram, Kwadwo A., et al.
Publicado: (2016)

An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults
por: Woods, Christopher W., et al.
Publicado: (2019)

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial
por: Mo, Zhao-Jun, et al.
Publicado: (2022)

A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers
por: Perkins, Daniel, et al.
Publicado: (2020)

Correlation between Commercial Anti-RBD IgG Titer and Neutralization Titer against SARS-CoV-2 Beta Variant
por: Poon, Rosana Wing-Shan, et al.
Publicado: (2021)

Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study
por: Wynne, Christopher John, et al.
Publicado: (2023)

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
por: Tokuda, Y, et al.
Publicado: (1999)

Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults
por: Miyaji, Karina Takesaki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ic52loio0lnsm33tu87fld85rf